# Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

Source: https://onco.cc/trials/nct03960840/  
OnCo record `nct03960840` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Ibrutinib in diffuse large b-cell lymphoma, run by Novartis Pharmaceuticals, active and no longer recruiting.

## Summary

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL is a phase 1/2 interventional study registered as NCT03960840 by Novartis Pharmaceuticals, with 217 participants enrolled, started 2019-06-26 and due to reach its primary completion in 2027-06-30. Interventions recorded: Rapcabtagene autoleucel single agent, Ibrutinib. Conditions listed: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03960840
- Phase: 1/2
- Setting: Phase I/II, Open Label, Multicenter Study of Rapcabtagene Autoleucel in Adult Patients With CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 217

## Sources

- ClinicalTrials.gov NCT03960840: https://clinicaltrials.gov/study/NCT03960840

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [Ibrutinib](https://onco.cc/drugs/ibrutinib/)
- companies: [Novartis](https://onco.cc/companies/novartis/)

---
JSON: https://onco.cc/api/v1/entities/nct03960840.json